Literature DB >> 2783337

Interleukin-2 therapy of human cancer: potential benefits versus toxicity.

R B Herberman1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783337     DOI: 10.1200/JCO.1989.7.1.1

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

Review 1.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

2.  Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state.

Authors:  W Emminger; W Emminger-Schmidmeier; C Peters; M Susani; R Hawliczek; P Höcker; H Gadner
Journal:  Blut       Date:  1990-10

Review 3.  The immunobiological effects of interleukin-2 in vivo.

Authors:  R A Janssen; N H Mulder; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

4.  Preoperative factors of prognostic significance in gastric cancer.

Authors:  H Johnson; C Belluco; S Masood; A Azama; L Kahn; L Wise
Journal:  J Natl Med Assoc       Date:  1995-06       Impact factor: 1.798

5.  Clinical results and immunologic effects of a mixed bacterial vaccine in cancer patients.

Authors:  H F Havas; R S Axelrod; M M Burns; D Murasko; M Goonewardene
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

6.  Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.

Authors:  D L Fraker; H N Langstein; J A Norton
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

7.  Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.

Authors:  D W Miles; D Aderka; H Engelmann; D Wallach; F R Balkwill
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.